Skip to content

Impact of Von Willebrand Factor and Its Multimers on Angiogenesis

Impact of Von Willebrand Factor and Its Multimers on Angiogenesis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04810702
Acronym
WILLANGIO
Enrollment
90
Registered
2021-03-23
Start date
2024-02-07
Completion date
2024-08-07
Last updated
2024-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Von Willebrand Diseases

Brief summary

The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and the clinical phenotype of the patients, in particular by looking for the presence of bleeding linked to the presence of angiodysplasias.

Interventions

OTHERno intervention

no intervention

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

For patients: * Patient with von Willebrand disease proven by genetic analysis of the VWF gene. * Lack of treatment that could interfere with angiogenesis. * Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research. For the control: * Patient with a normal coagulation report * Absence of abnormal hemorrhagic symptoms * Lack of notion of angiodysplasia. * Lack of treatment that could interfere with angiogenesis. * Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.

Exclusion criteria

* Patient under guardianship or curatorship. * Pregnant and lactating women. * Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old. * Treatment which may interfere with angiogenesis.

Design outcomes

Primary

MeasureTime frameDescription
To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest1 yearCompare the distribution of multimers assays between different groups of patients and the control group

Secondary

MeasureTime frameDescription
To study the relationship between the distribution of multimers and the clinical phenotype of patients, and in particular the presence of angiodysplasias1 yearTo study the correlation between the clinical phenotype and the assays of angiogenesis proteins
To study the relationship between the markers of interest and the clinical phenotype of patients, and in particular the presence of angiodysplasias1 yearTo study the correlation between the clinical phenotype and the distribution of multimers

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026